Mechanisms of selective therapeutic synergy of PARP-inhibition and CTLA4 blockade engaged by interferon-gamma in the ovarian tumor microenvironment
干扰素-γ在卵巢肿瘤微环境中选择性抑制 PARP 和 CTLA4 阻断的协同治疗机制
基本信息
- 批准号:10334447
- 负责人:
- 金额:$ 35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-02-18 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptionAntibodiesAntibody TherapyAreaBRCA1 MutationBRCA1 geneBRCA2 MutationBiological MarkersBlood specimenCD8-Positive T-LymphocytesCTLA4 blockadeCTLA4 geneCancer BiologyCancer ModelCell CycleCell DeathCellsClinicalClinical DataClinical TrialsCorrelative StudyCytotoxic agentDataDevelopmentDiseaseDisease OutcomeEnvironmentFailureGene ExpressionGoalsImmuneImmunobiologyImmunotherapyIn VitroInterferon Type IIInterferonsKnowledgeLeukocytesLinkLymphocyteMalignant NeoplasmsMalignant neoplasm of ovaryMediatingModelingMusPatient-Focused OutcomesPatientsPhasePoly Adenosine Diphosphate RibosePolymeraseProductionPublishingRecurrenceRecurrent diseaseRegimenResistanceSampling StudiesSignal TransductionSolid NeoplasmT-LymphocyteTestingTherapeuticTranslationsTreatment EfficacyTumor ImmunityWomanWorkbaseblood treatmentcancer therapyclinical efficacyclinical translationcombinatorialcytotoxiccytotoxicitygenetic signatureimmune checkpointimmune checkpoint blockadeimmunogenicimmunoregulationin vivoinhibitormelanomamortalitymutation carrierneoplastic cellnovelovarian neoplasmpre-clinicalpredicting responsepredictive markerrecruitresponseresponse biomarkersynergismtargeted agenttherapy resistanttreatment effecttreatment responsetumortumor microenvironment
项目摘要
The high mortality rate associated with ovarian cancer results from the failure of tumor-directed therapy to
produce lasting treatment responses. Durable survival in patients with other solid tumors has recently been
achieved using immune checkpoint antibodies, however similar results have not been observed in women
with ovarian cancer. Published work from our lab demonstrates that combining poly(adenosine
diphosphate-ribose) polymerase (PARP) inhibitors with immune checkpoint blockade can achieve long-
term survival in ovarian cancer models. Early results from an ongoing clinical trial have now demonstrated
significant clinical efficacy of this regimen in women with recurrent ovarian cancer. Here we propose to
dissect the mechanisms responsible for the observed therapeutic synergy of this combination to enable
the optimal integration of immune therapy with cytotoxic regimens for long-term benefit in women with
ovarian cancer. The scientific premise for this study is based accumulating evidence of a dynamic
interaction between tumor cells and the tumor microenvironment (TME) that regulates treatment response
and disease outcomes. Our work additionally demonstrates that the TME interacts directly with tumor-
targeted agents to enhance tumor clearance. Combined PARP-inhibition and CTLA4 blockade resulted in
a significant increase in the proportion of T cells producing IFNγ in the TME, an effect which persisted long
after completion of therapy. We found that IFNγ enhanced tumor cytotoxicity in response to PARP-
inhibition through a cell-intrinsic mechanism in vitro, and that IFNγ was required for the survival benefit
observed in vivo. Evidence that conditions in the tumor environment significantly modulate the therapeutic
efficacy of PARP-inhibitors, termed “contextual synthetic lethality”, presents an opportunity to maximize
patient outcomes and target treatment effects to the TME. Here we propose to dissect the cell-intrinsic
and –extrinsic mechanisms responsible for the observed therapeutic synergy of PARP inhibitors and
CTLA4 blockade and to develop a treatment predictive biomarker linked to these mechanisms for clinical
translation. With the rapid adoption of immune checkpoint antibodies and PARP-inhibitors for the treatment
of ovarian cancer and other tumor types, this proposal has potential for immediate clinical impact through
current and planned clinical trials.
卵巢癌相关的高死亡率是由于肿瘤导向治疗失败所致。
产生持久的治疗反应。最近,患有其他实体肿瘤的患者的持久存活率
使用免疫检查点抗体,然而在女性中没有观察到类似的结果
患有卵巢癌。我们实验室发表的研究表明,结合多(腺苷)
具有免疫检查点阻断的二磷酸核糖聚合酶(PARP)抑制剂可实现长时间的
卵巢癌模型的长期存活率。一项正在进行的临床试验的早期结果现在证明
该方案对女性复发性卵巢癌有显著的临床疗效。在此,我们建议
剖析导致观察到的这种组合的治疗协同作用的机制
免疫治疗与细胞毒疗法的最佳结合对女性慢性粒细胞白血病患者的长期益处
卵巢癌。这项研究的科学前提是积累动态的证据
肿瘤细胞与调节治疗反应的肿瘤微环境(TME)的相互作用
以及疾病的结果。我们的工作还表明,TME与肿瘤直接相互作用-
靶向药物以提高肿瘤清除能力。PARP抑制和CTLA4联合阻断导致
TME中产生干扰素γ的T细胞比例显著增加,这一效应持续了很长时间
在完成治疗后。我们发现干扰素γ增强了对PARP-1的肿瘤细胞毒作用。
在体外通过细胞内在机制抑制,干扰素γ是生存益处所必需的
活体观察。有证据表明,肿瘤环境中的条件显著调节了治疗
PARP抑制剂的有效性,被称为“背景合成致死性”,提供了一个最大限度地
TME的患者预后和靶向治疗效果。在这里,我们建议剖析细胞固有的
和-外在机制负责观察到的PARP抑制剂和
阻断CTLA4并开发与这些机制相关的治疗预测生物标记物用于临床
翻译。迅速采用免疫检查点抗体和PARP抑制剂进行治疗
对于卵巢癌和其他类型的肿瘤,这项建议可能通过以下方式立即产生临床影响
目前和计划中的临床试验。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sarah Foster Adams其他文献
Sarah Foster Adams的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sarah Foster Adams', 18)}}的其他基金
Mechanisms of selective therapeutic synergy of PARP-inhibition and CTLA4 blockade engaged by interferon-gamma in the ovarian tumor microenvironment
干扰素-γ在卵巢肿瘤微环境中选择性抑制 PARP 和 CTLA4 阻断的协同治疗机制
- 批准号:
10098009 - 财政年份:2019
- 资助金额:
$ 35万 - 项目类别:
Mechanisms of selective therapeutic synergy of PARP-inhibition and CTLA4 blockade engaged by interferon-gamma in the ovarian tumor microenvironment
干扰素-γ在卵巢肿瘤微环境中选择性抑制 PARP 和 CTLA4 阻断的协同治疗机制
- 批准号:
10554264 - 财政年份:2019
- 资助金额:
$ 35万 - 项目类别:
相似海外基金
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 35万 - 项目类别:
Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 35万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 35万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 35万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 35万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 35万 - 项目类别:
EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 35万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 35万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 35万 - 项目类别:
Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 35万 - 项目类别:
Standard Grant